Ground-breaking Alzheimer’s drug may be ‘beginning of the end’ for disease
2 years ago

Ground-breaking Alzheimer’s drug may be ‘beginning of the end’ for disease

The Telegraph  

A drug which slows down Alzheimer’s and reduces memory decline may be “the beginning of the end” for the disease, scientists believe. “These exciting findings represent a major step forward for dementia research and could herald a new era for people with Alzheimer’s disease,” she said. “This is the first time a drug has been shown to both reduce the disease in the brain and slow memory decline in clinical trials.” Dr Richard Oakley, associate director of Research at Alzheimer’s Society, said the drug “could be a game-changer” if ongoing research finds it is as effective as believed. Corresponding author Dr Qihao Guo, of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, said: “Urinary formic acid showed an excellent sensitivity for early Alzheimer’s screening.

Research Disease Trial Early Drug Step Formic Acid  beginning  disease  findings  dementia  trial  alzheimers  groundbreaking  step  early  research  end  drug  treatment

History of this topic

New Alzheimer's drug: only a few eligible for treatment
1 month, 1 week ago

New Alzheimer's drug: only a few eligible for treatment

NL Times  

It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the slowing agent that is still allowed on the European market by the European Medicines Agency. That is why Alzheimer Nederland calls for a fast track "so that patients and their families are not unnecessarily in uncertainty for a long …

Alzheimer's timeline shows changes start as trickle, become torrent
1 month, 2 weeks ago

Alzheimer's timeline shows changes start as trickle, become torrent

NPR  

Alzheimer's timeline shows changes start as trickle, become torrent toggle caption koto_feja/Getty Images/E+ A study of cells from 84 cadaver brains suggests that Alzheimer's has two distinct phases, and that one type of neuron is especially vulnerable. The study also found evidence that a small subset of neurons known as somatostatin inhibitory neurons begin to die off during the early …

What are the symptoms and treatments for Alzheimer’s – as new drug is rejected
4 months ago

What are the symptoms and treatments for Alzheimer’s – as new drug is rejected

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …

Alzheimer’s drug that can slow disease gets backing from FDA advisers
6 months, 2 weeks ago

Alzheimer’s drug that can slow disease gets backing from FDA advisers

Associated Press  

WASHINGTON — A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia caused by the brain-robbing disease. Food and Drug Administration advisers voted unanimously that the drug’s ability to slow the disease outweighs its risks, including side effects like brain …

It’s the first drug shown to slow Alzheimer’s. Why is it off to a slow start?
8 months, 1 week ago

It’s the first drug shown to slow Alzheimer’s. Why is it off to a slow start?

Associated Press  

The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. “As we learn more, we’ll expand and extend it.” The Mayo Clinic in Rochester, Minnesota, started using Leqembi in October but only for patients …

Why is this Alzheimer’s breakthrough so important?
1 year, 5 months ago

Why is this Alzheimer’s breakthrough so important?

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Scientists found that donanemab was able to slow clinical …

Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety risk
1 year, 5 months ago

Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety risk

Associated Press  

WASHINGTON — Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved Leqembi from Japanese drugmaker Eisai. “Diabetes doesn’t have a cure either — it doesn’t mean you …

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’
1 year, 5 months ago

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’

The Telegraph  

The NHS has just 88 positron emission tomography scanners which can detect amyloid plaques in the brain, one of the lowest per capita in the developed world. Hilary Evans, the chief executive of Alzheimer’s Research UK said: “Probably only two per cent of the people who could benefit from these drugs would necessarily get them because of those hurdles in …

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor
1 year, 5 months ago

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor

NL Times  

Alzheimer's used to be a disease that could not be cured. On Monday, however, the results of the second new drug for Alzheimer's will be announced, and that seems to herald a new era, says neurologist Niels Prins, director of the Brain Research Center. "It will be possible to counteract the disease, and that has never been done before in …

Opinion: New Alzheimer’s drugs are costly and controversial. Are we going about this all wrong?
1 year, 6 months ago

Opinion: New Alzheimer’s drugs are costly and controversial. Are we going about this all wrong?

LA Times  

An illustration depicting neurons in a brain affected by Alzheimer’s disease, with abnormal accumulations of beta-amyloid and tau proteins shown in brown and blue, respectively. The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. Eli Lilly’s stock price jumped 6.7% after it announced positive results …

Breakthrough Alzheimer’s drugs could be blocked by NHS, campaigners warn
1 year, 6 months ago

Breakthrough Alzheimer’s drugs could be blocked by NHS, campaigners warn

The Telegraph  

The first drugs to slow dementia could be denied to NHS patients because of rationing, campaigners and health experts have warned. Recent weeks have seen breakthroughs in Alzheimer’s research, sparking hopes of “the beginning of the end” of the disease, but the UK’s leading dementia charity fears the drugs will be blocked by NHS rationing bodies. Alzheimer’s Research UK has …

Alzheimer’s treatments ready by 2040, says leading expert
1 year, 8 months ago

Alzheimer’s treatments ready by 2040, says leading expert

The Telegraph  

Alzheimer’s treatments will be ready by 2040, a leading expert has predicted. “Things are speeding up and improving all the time,” Prof Williams, who has studied Alzheimer’s for 30 years, told the BBC. “I’ve learnt more in the last seven years than I did in the previous 20.” There will never be one simple cure She said her study of …

EXPLAINER: New drug slows Alzheimer’s but comes with caveats
1 year, 11 months ago

EXPLAINER: New drug slows Alzheimer’s but comes with caveats

Associated Press  

WASHINGTON — A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease. In Eisai’s 18-month study of nearly 1,800 people, Leqembi appeared to delay early-stage patients from getting worse by about five months. People who got the drug still worsened but not as rapidly as those …

U.S. approves Alzheimer’s drug that modestly slows disease
1 year, 11 months ago

U.S. approves Alzheimer’s drug that modestly slows disease

LA Times  

This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh. Last week, a congressional report found that FDA’s approval …

Explained | Will new drug slow progress of Alzheimer’s?
2 years ago

Explained | Will new drug slow progress of Alzheimer’s?

The Hindu  

The story so far: In late November, news of the success of a drug to reduce cognitive decline in patients with Alzheimer’s disease burst on the horizon with all the promise of being a silver bullet. This class of drugs does precisely that.” As per the NEJM paper, the clinical trial, conducted over 18-months, a multi-centre, double-blind, phase 3 trial, …

Is the new drug lecanemab a breakthrough for Alzheimer’s?
2 years ago

Is the new drug lecanemab a breakthrough for Alzheimer’s?

Hindustan Times  

There’s news in the world of Alzheimer’s research. In a phase three trial, drug companies Biogen and Eisai reported this week that lecanemab, an experimental monoclonal antibody, reduced cognitive decline caused by the disease by 27% after 18 months. This trial proves that Alzheimer’s disease can be treated," Bart De Strooper, Director of the UK Dementia Research Institute, told reporters. …

Drug slows Alzheimer’s but can it make a real difference?
2 years ago

Drug slows Alzheimer’s but can it make a real difference?

Associated Press  

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening — but the anxiously awaited new data leaves unclear how much difference that might make in people’s lives. But Dr. Ron Petersen, an Alzheimer’s expert at the Mayo Clinic, said the drug’s effect was “a modest one but I think it’s clinically meaningful” -- because even a few months’ …

Breakthrough: A drug slows Alzheimer’s by 5 months, but will it make a big difference?
2 years ago

Breakthrough: A drug slows Alzheimer’s by 5 months, but will it make a big difference?

Firstpost  

On Tuesday, Japanese drugmaker Eisai and its US partner Biogen reported that an experimental Alzheimer’s drug had modestly slowed the brain disease’s inevitable worsening. However, it is unclear how much of a difference this would make in people’s lives An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much …

New drug appears to slow Alzheimer’s, but can it make a real difference?
2 years ago

New drug appears to slow Alzheimer’s, but can it make a real difference?

LA Times  

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner, Biogen, had announced earlier this fall that the drug, lecanemab, appeared to work, a badly needed bright spot after repeated disappointments in the quest for …

Drug that reverses dementia will be wasted without better diagnosis rates, experts warn
2 years ago

Drug that reverses dementia will be wasted without better diagnosis rates, experts warn

The Telegraph  

The latest published data shows that as of 2019, Britain had just 70 PET-CT scanning locations, less than half the number of those available in comparable EU countries. “We need everyone to be told which disease is causing their dementia symptoms, and if they have Alzheimer’s disease, a follow-up scan or CSF test to check if they are amyloid positive …

Alzheimer's disease is caused by decline in levels of amyloid-beta: Research
2 years, 2 months ago

Alzheimer's disease is caused by decline in levels of amyloid-beta: Research

Hindustan Times  

New research supports the hypothesis that Alzheimer's disease is caused by a decline in levels of a protein called amyloid-beta. "The paradox is that so many of us accrue plaques in our brains as we age, and yet so few of us with plaques go on to develop dementia," said Espay, professor of neurology in the UC College of Medicine, …

Alzheimer’s drug shows promise in early results of study
2 years, 2 months ago

Alzheimer’s drug shows promise in early results of study

Associated Press  

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. …

'Huge breakthrough' for Alzheimer's
2 years, 2 months ago

'Huge breakthrough' for Alzheimer's

Daily Mail  

An experimental Alzheimer's drug slows the mental deterioration of patients battling the earliest stages of the cruel disease by more than a quarter, promising trial results revealed today. An experimental Alzheimer's drug, called lecanemab, has significantly slowed cognitive and functional decline by 27 per cent in a large patient trial Dr Susan Kohlhaas, director of research at Alzheimer's Research UK, …

Will we ever cure cruel Alzheimer's?
2 years, 5 months ago

Will we ever cure cruel Alzheimer's?

Daily Mail  

It was officially described 115 years ago. MailOnline looks at some of the potential breakthroughs that could one day lead to curing or reversing Alzheimer's: Vaccines and antibodies, brain zapping helmets, oxygen therapy and stem cells are just some of the areas experts are exploring in the hunt for a cure for Alzheimer's A study by researchers at the University …

Why the world's still waiting for a dementia cure, and what we can do in the meantime
2 years, 6 months ago

Why the world's still waiting for a dementia cure, and what we can do in the meantime

ABC  

Frank Freschi knows how cruel Alzheimer's disease can be. Many researchers believe that the most common form of dementia, Alzheimer's disease, may actually start decades before thinking and memory start to decline. "We now understand that we must go even earlier, before the onset of cognitive impairment into the preclinical stages of the disease," says the Florey Institute's Colin Masters …

Change at the top for Biogen after Alzheimer’s drug flops
2 years, 7 months ago

Change at the top for Biogen after Alzheimer’s drug flops

Associated Press  

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer’s drug Aduhelm less than a year after the medication’s launch triggered a backlash from experts, doctors and insurers. For now, Biogen said it is “substantially eliminating” spending on Aduhelm as part of a $1 billion dollar cost-saving plan designed to refocus the company’s flagging biotech business. Aduhelm …

Does new Alzheimer’s drug work? Answers may miss 2030 target
3 years, 5 months ago

Does new Alzheimer’s drug work? Answers may miss 2030 target

Associated Press  

WASHINGTON — When a controversial Alzheimer’s drug won U.S. approval, surprise over the decision quickly turned to shock at how long it might take to find out if it really works — nine years. “We think nine years is unacceptable and our expectation is that it will happen in a much shorter time frame,” said Maria Carrillo of the Alzheimer’s …

Alzheimer’s drug stirs hope for patients, worry for doctors
3 years, 5 months ago

Alzheimer’s drug stirs hope for patients, worry for doctors

LA Times  

Michele Hall, who has early Alzheimer’s, calls the new drug Aduhelm “the first tiny glimmer of hope” that she might have more quality time with her husband and their three adult children. In the weeks since a new Alzheimer’s drug was approved, hopeful patients have bombarded Dr. Alireza Atri with calls and emails about a treatment that has sparked both …

Opinion: New Alzheimer’s drug sets dangerous precedent
3 years, 6 months ago

Opinion: New Alzheimer’s drug sets dangerous precedent

CNN  

Editor’s Note: Reshma Ramachandran, MD, MPP is a physician-fellow at the National Clinician Scholars Program at the Yale School of Medicine whose research and policy work centers on the realignment of incentives to ensure patients access to affordable, effective, and safe treatment. CNN — Last week, the US Food and Drug Administration approved aducanumab as a treatment for Alzheimer’s disease …

Why The FDA's Approval Of A New Alzheimer's Drug Should Worry You
3 years, 6 months ago

Why The FDA's Approval Of A New Alzheimer's Drug Should Worry You

Huff Post  

LOADING ERROR LOADING You might expect Mariah Robertson to applaud last week’s approval of a new drug for Alzheimer’s disease. In the meantime, the Aduhelm decision could set a precedent for how the FDA approaches other treatments ― an “enormously risky move,” as STAT writer Matthew Herper put it, “that could accelerate the public’s access to medicines but upend the …

FDA adviser resigns over approval of new Alzheimer’s drug
3 years, 6 months ago

FDA adviser resigns over approval of new Alzheimer’s drug

CNN  

CNN — A member of a US Food and Drug Administration advisory committee said Wednesday he had resigned over the agency’s approval of a new Alzheimer’s drug. “While I disagree with the decision to approve aducanumab, we in the clinical care and clinical research worlds will simply have to learn to adapt to the new circumstances.” The FDA’s advisers said …

US Approves First New Alzheimer's Drug in Almost Two Decades
3 years, 6 months ago

US Approves First New Alzheimer's Drug in Almost Two Decades

News 18  

The United States on Monday approved a drug called Aduhelm to treat patients with Alzheimer’s, the first new medicine against the disease in almost two decades and the first to address cognitive decline linked to the condition. The decision was highly anticipated but also contentious, because an independent expert panel convened by the regulatory Food and Drug Administration last November …

FDA Approves Much-Debated Alzheimer’s Drug Panned By Experts
3 years, 6 months ago

FDA Approves Much-Debated Alzheimer’s Drug Panned By Experts

Huff Post  

LOADING ERROR LOADING WASHINGTON — Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. The Food and Drug Administration said it granted approval to the drug developed by Biogen for patients with Alzheimer’s disease. …

Discover Related